Feed/Companies/Atavistik Bio

Atavistik Bio

As of 14 Oct 2026, Atavistik Bio has raised $120M across 1 verified round on record; latest: $120 million Series B led by Nextech Invest and The Column Group, announced 18 Dec 2025.

BUILT ON

Visit site

Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT).

atavistikbio.comLinkedInCambridge, Mass.

LATEST ROUND

Series B

$120M · 2025-12-18

RAISED ON RECORD · USD

$120M

across 1 verified round

INVESTORS

2 leads

SOURCES

from 2 publishers

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$120M · 2025-12-18

[ HISTORY ]

led by Nextech Invest, The Column Group

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$120M	2025-12-18	Nextech Invest, The Column Group	No recent discussion
2 sources [ VERIFIED ] read against 2 sources

Atavistik Bio

Company

Rounds

Sources

Profile

Investors

Atavistik Bio

Rounds

Profile

Sources

Series B$120M2025-12-182 sources

Investors

Series B$120M2025-12-184 investors